(Q33307663)

25 July 2017

1 reference

title

Chemotherapy induced diarrhea (English)

1 reference

25 July 2017

0 references

1 reference

Gillian Richardson

1

1 reference

25 July 2017

Roxanne Dobish

series ordinal

2

1 reference

25 July 2017

publication date

1 December 2007

1 reference

Journal of Oncology Pharmacy Practice

25 July 2017

published in

1 reference

25 July 2017

volume

13

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

181-198

1 reference

Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Management of cancer treatment-related diarrhea. Issues and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Diarrhea in terminally ill patients: Pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Intestinal ion transport and the pathophysiology of diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Novel agents that potentially inhibit irinotecan-induced diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

New approaches to prevent intestinal toxicity of irinotecan-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Benefit-risk assessment of irinotecan in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Control of irinotecan-induced diarrhea by octreotide after loperamide failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Two schedules of second-line irinotecan for metastatic colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Overview of chemotherapy-induced diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Intestinal microflora and digestive toxicity of irinotecan in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

An overview of clinical studies with racecadotril in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207077335

21 January 2018

Identifiers

DOI

10.1177/1078155207077335

1 reference

25 July 2017

1 reference